Login to Your Account

Genaera Discontinues 2 Studies, Narrows Work In Obesity, Asthma

By Jennifer Boggs

Friday, July 6, 2007
Nearly three months after Genaera Corp. said it planned to divest noncore assets, the company halted ongoing Phase II programs in cystic fibrosis and prostate cancer to conserve cash for its early stage obesity drug, trodusquemine. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription